CADET® BRAF and CADET® BRAF-PLUS
Accurate canine bladder and prostate cancer test.
The power of molecular diagnostics
CADET®BRAFevaluates urine samples from dogs for the presence of cells containing a mutation for canine bladder/prostate cancer (TCC/UC). It’s cutting-edge technology that is accurate, affordable, and convenient for both veterinarian and pet owner.
Download the Test Request Form
Achieve accurate and early diagnosis of TCC/UC
CADET®BRAFis a highly sensitive test designed to monitor the b-raf mutation in TCC/UC cases during the course of their treatment, for therapeutic response and relapse. CADET®BRAFtesting can be used for both the rapid, non-invasive assessment of dogs displaying clinical signs consistent with TCC/UC and for confirmed cases undergoing treatment.
How CADET®BRAF is used in a clinical setting
CADET®BRAF evaluates free-catch urine samples from dogs for the presence of cells harboring the BRAF mutation or specific copy number variations associated with TCC/UC. The assays identify 95% of TCC/UC cases. The extremely low limit of detection of 10 mutation-bearing cells in a urine sample allows early diagnosis of a developing TCC/UC, often several months before any advanced clinical signs associated with the cancer become evident.
Educational Webinar
Using Molecular Diagnostics to Detect Canine Bladder and Prostate Cancer
In this one hour webinar, with Dr. Sue Ettinger, DVM, DACVIM (Oncology), you will learn more on detecting both prostate and bladder cancer in canines utilizing the CADET® BRAFurine test. This test allows for early diagnosis in clinical cases with recurrent, complicated, or antibiotic-resistant urinary tract infections presenting with hematuria without ultrasonographic evidence of a bladder mass.
Dr. Sue Ettingerwill share how this new cutting edge test will simplify diagnosing these rare cancers in the hope of achieving better health outcomes.
CADET®BRAF-PLUS provides further evaluation of those dogs that present with clinical signs consistent with TCC/UC, but for which no BRAF mutation is detected. Our comprehensive analysis of thousands of clinical specimens has shown that CADET®BRAF-PLUS detects more than 2/3 of the TCC/UC cases that are not identified by CADET®BRAF.
Clinical indications for when to use CADET® BRAFandBRAF-PLUS
- Clinical cases presenting with hematuria, stranguria, and/or urinary incontinence with diagnostic imaging evidence of a mass in the bladder.
- Confirmation of the TCC/UC diagnosis of a bladder mass from a stained cytology slide following ultrasonography and cytological examination of a fine-needle aspirate from tumor-bearing cells.
- During chemotherapy to monitor treatment success by decreased levels of BRAF mutation detection, or to monitor cancer relapse by recurrence of BRAF mutation tumor-bearing cells.
Early detection in high-risk dog breeds such as terriers, Shetland and Australian sheep dogs, cattle dogs, beagles, and border collies that are 6 years and older.
- Early diagnosis in clinical cases with recurrent, complicated, or antibiotic-resistant urinary tract infections presenting with hematuria without ultrasonographic evidence of a bladder mass.
Search our extensive list of tests.
